CYT-108 Development is De-Risked
Cytonics has already successfully commercialized a therapy for osteoarthritis. This FDA-approved medical device (the Autologous Protease Inhibitor Concentrate therapy, or “APIC”) leverages the cartilage-protecting properties of a naturally occurring blood protein, called alpha-2-macroglobulin (A2M), by purifying the A2M from a patient’s own blood and injecting it into their arthritic joints.
The clinical and commercial success of our first-generation APIC therapy is a testament to A2M’s ability to treat osteoarthritis. But why stop there?
Cytonics’ next-generation treatment for OA, “CYT-108”, is a genetically modified, synthetic variant of the natural A2M protein that has been engineered to increase its potency and cartilage-restoring abilities.
The logic is simple: We already know that A2M works as a treatment for OA… and now we have developed a superior, patented version. Essentially, we have “improved on Nature’s design.”